Caries Res 2004;38:230–235

A Caries Vaccine?

The State of the Science of Immunization against Dental Caries

Russell M.W.a · Childers N.K.b · Michalek S.M.c · Smith D.J.d · Taubman M.A.d
aDepartments of Oral Biology and Microbiology and Immunology, University at Buffalo, Buffalo, N.Y., Departments of bOral Biology and cMicrobiology, University of Alabama at Birmingham, Birmingham, Ala., and dDepartment of Immunology, Forsyth Institute, Boston, Mass., USA
email Corresponding Author

 goto top of outline Key Words

  • Mutans streptococci
  • Salivary IgA antibodies
  • Vaccine antigen
  • Mucosal immunization

 goto top of outline Abstract

Studies performed in numerous laboratories over several decades have demonstrated the feasibility of immunizing experimental rodents or primates with protein antigens derived from Streptococcus mutans or Streptococcus sobrinus against oral colonization by mutans streptococci and the development of dental caries. Protection has been attributed to salivary IgA antibodies which can inhibit sucrose-independent or sucrose-dependent mechanisms of streptococcal accumulation on tooth surfaces according to the choice of vaccine antigen. Strategies of mucosal immunization have been developed to induce high levels of salivary antibodies that can persist for prolonged periods and to establish immune memory. Studies in humans show that salivary antibodies to mutans streptococci can be induced by similar approaches, and that passively applied antibodies can also suppress oral re-colonization by mutans streptococci. Progress towards practical vaccine development requires evaluation of candidate vaccines in clinical trials. Promising strategies of passive immunization also require further clinical evaluation.

Copyright © 2004 S. Karger AG, Basel

 goto top of outline References
  1. Ajdic D, McShan WM, McLaughlin RE, Savic G, Chang J, Carson MB, Primeaux C, Tian RY, Kenton S, Jia HG, Lin SP, Qian YD, Li SL, Zhu H, Najar F, Lai HS, White J, Roe BA, Ferretti JJ: Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci USA 2002;99:14434–14439.
  2. Caufield P, Cutter G, Dasanayake A: Initial acquisition of mutans streptococci by infants: Evidence for a discrete window of infectivity. J Dent Res 1993;72:37–45.
  3. Challacombe SJ, Russell MW, Hawkes JE, Bergmeier LA, Lehner T: Passage of immunoglobulins from plasma to the oral cavity in rhesus monkeys. Immunology 1978;35:923–931.
  4. Childers NK, Li F, Kirk K, Dasanayake AP, Kim J-G, Michalek SM: Nasal but not tonsillar immunization of humans with Streptococcus mutans antigens primes for responses 2 years after an initial immunization (abstract 1721). J Dent Res 2003;82(special issue).
  5. Childers NK, Tong G, Li F, Dasanayake AP, Kirk K, Michalek SM: Humans immunized with Streptococcus mutans antigens by mucosal routes. J Dent Res 2002;81:48–52.
  6. Childers NK, Tong G, Michalek SM: Nasal immunization of humans with dehydrated liposomes containing Streptococcus mutans antigen. Oral Microbiol Immunol 1997;12:329–335.
  7. Childers NK, Tong G, Mitchell S, Kirk K, Russell MW, Michalek SM: A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses. Infect Immun 1999;67:618–623.
  8. Childers NK, Zhang SS, Michalek SM: Oral immunization of humans with dehydrated liposomes containing Streptococcus mutans glucosyltransferase induces salivary immunoglobulin A2 antibody responses. Oral Microbiol Immunol 1994;9:146–153.
  9. Eastcott JW, Orr N, Smith DJ, Hayden TL, Taubman MA: Expression and delivery of GTF peptides in Salmonella enterica (abstract 3886). J Dent Res 2002;81(special issue A).
  10. Hajishengallis G, Hollingshead SK, Koga T, Russell MW: Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 1995;154:4322–4332.
  11. Hajishengallis G, Michalek SM, Russell MW: Persistence of serum and salivary antibody responses after oral immunization with a bacterial protein antigen genetically linked to the A2/B subunits of cholera toxin. Infect Immun 1996;64:665–667.
  12. Hamada S, Horikoshi T, Minami T, Kawabata S, Hiraoka J, Fujiwara T, Ooshima T: Oral passive immunization against dental caries in rats by use of hen egg yolk antibodies specific for cell-associated glucosyltransferase of Streptococcus mutans. Infect Immun 1991;59:4161–4167.
  13. Harokopakis E, Hajishengallis G, Greenway TE, Russell MW, Michalek SM: Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of co-expressed cholera toxin A2/B subunits. Infect Immun 1997;65:1445–1454.
  14. Harrod T, Martin M, Russell MW: Long-term persistence and recall of immune responses in aged mice after mucosal immunization. Oral Microbiol Immunol 2001;16:170–177.
  15. Hatta H, Tsuda K, Ozeki M, Kim M, Yamamoto T, Otake S, Hirasawa M, Katz J, Childers NK, Michalek SM: Passive immunization against dental plaque formation in humans: Effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Caries Res 1997;31:268–274.
  16. Huang Y, Hajishengallis G, Michalek SM: Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter. Infect Immun 2001;69:2154–2161.
  17. Jenkinson HF, Lamont RJ: Streptococcal adhesion and colonization. Crit Rev Oral Biol Med 1997;8:175–200.
  18. Jespersgaard C, Hajishengallis G, Huang Y, Russell MW, Smith DJ, Michalek SM: Protective immunity against Streptococcus mutans infection in mice after intranasal immunization with the glucan-binding region of S. mutans glucosyltransferase. Infect Immun 1999;67:6543–6549.
  19. Koga T, Oho T, Shimazaki Y, Nakano Y: Immunization against dental caries. Vaccine 2002;20:2027–2044.
  20. Lehner T, Caldwell J, Smith R: Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries. Infect Immun 1985;50:796–799.
  21. Lehner T, Challacombe SJ, Caldwell J: Immunological basis for vaccination against dental caries in rhesus monkeys. J Dent Res 1976;55(special issue C):166.
  22. Li F, Michalek SM, Dasanayake AP, Li Y, Kirk K, Childers NK: Intranasal immunization of humans with Streptococcus mutans antigens: Low dose differentiates responses to soluble versus liposomal antigens. Oral Microbiol Immunol 2003;18:271–277.
  23. Li Y, Caufield PW: The fidelity of initial acquisition of mutans streptococci by infants from their mothers. J Dent Res 1995;74:681–685.
  24. Loesche WJ: Role of Streptococcus mutans in human dental decay. Microbiol Rev 1986;50:353–380.
  25. Loimaranta V, Carlén A, Olsson J, Tenovuo J, Syväoja EL, Korhonen H: Concentrated bovine colostral whey proteins from Streptococcus mutans/Strep. sobrinus immunized cows inhibit the adherence of Strep. mutans and promote the aggregation of mutans streptococci. J Dairy Res 1998;65:599–607.
  26. Ma JKC, Hiatt A, Hein M, Vine ND, Wang F, Stabila P, Van Dolleweerd C, Mostov K, Lehner T: Generation and assembly of secretory antibodies in plants. Science 1995;268:716–719.
  27. Ma JKC, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, Hein MB, Lehner T: Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 1998;4:601–606.
  28. Ma JKC, Hunjan M, Smith R, Kelly C, Lehner T: An investigation into the mechanism of protection by local passive immunization with monoclonal antibodies against Streptococcus mutans. Infect Immun 1990;58:3407–3414.
  29. Martin MH, Metzger DJ, Michalek SM, Connell TD, Russell MW: Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins, LT-IIa and LT-IIb. Infect Immun 2000;68:281–287.
  30. Michalek SM, Childers NK, Katz J, Dertzbaugh M, Zhang S, Russell MW, Macrina FL, Jackson S, Mestecky J: Liposomes and conjugate vaccines for antigen delivery and induction of mucosal immune responses. Adv Exp Med Biol 1992;327:191–198.
  31. Mitoma M, Oho T, Michibata N, Okano K, Nakano Y, Fukuyama M, Koga T: Passive immunization with bovine milk containing antibodies to a cell surface protein antigen-glucosyltransferase fusion protein protects rats against dental caries. Infect Immun 2002;70:2721–2724.
  32. Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR (eds): Mucosal Immunology. San Diego, Academic Press, 1999.
  33. Russell MW: Potential for vaccines in the prevention of caries lesions. Oper Dent 2001;suppl 6:51–60.
  34. Russell MW: Mucosal immunity; in Ellis RW, Brodeur BR (eds): New Bacterial Vaccines. Georgetown, Landes Bioscience, 2003.
  35. Russell MW, Hajishengallis G, Childers NK, Michalek SM: Secretory immunity in defense against cariogenic mutans streptococci. Caries Res 1999;33:4–15.
  36. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM: Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect Immun 1996;64:1272–1283.
  37. Russell MW, Wu H-Y: Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit. Infect Immun 1991;59:4061–4070.
  38. Russell RRB, Beighton D, Cohen B: Immunization of monkeys (Macaca fascicularis) with antigens purified from Streptococcus mutans. Br Dent J 1982;152:81–84.
  39. Smith DJ: Dental caries vaccines: Prospects and concerns. Crit Rev Oral Biol Med 2002;13:335–349.
  40. Smith DJ, King WF, Akita H, Taubman MA: Association of salivary immunoglobulin A antibody and initial mutans streptococcal infection. Oral Microbiol Immunol 1998;13:278–285.
  41. Smith DJ, King WF, Barnes LA, Peacock Z, Taubman MA: Immunogenicity and protective immunity induced by synthetic peptides associated with putative immunodominant regions of Streptococcus mutans glucan-binding protein B. Infect Immun 2003;71:1179–1184.
  42. Smith DJ, King WF, Godiska R: Passive transfer of immunoglobulin Y antibody to Streptococcus mutans glucan binding protein B can confer protection against experimental dental caries. Infect Immun 2001;69:3135–3142.
  43. Smith DJ, Taubman MA: Oral immunization of humans with Streptococcus sobrinus glucosyltransferase. Infect Immun 1987;55:2562–2569.
  44. Smith DJ, Taubman MA: Effect of local deposition of antigen on salivary immune responses and reaccumulation of mutans streptococci. J Clin Immunol 1990;10:273–281.
  45. Smith DJ, Taubman MA: Ontogeny of immunity to oral microbiota in humans. Crit Rev Oral Biol Med 1992;3:109–133.
  46. Smith DJ, Trantolo DJ, King WF, Gusek EJ, Fackler PH, Gresser JD, De Souza VL, Wise DL: Induction of secretory immunity with bioadhesive poly(D,L-lactide-co-glycolide) microparticles containing Streptococcus sobrinus glucosyltransferase. Oral Microbiol Immunol 2000;15:124–130.
  47. Takahashi I, Okahashi N, Matsushita K, Tokuda M, Kanamoto T, Munekata E, Russell MW, Koga T: Immunogenicity and protective effect against oral colonization by Streptococcus mutans of synthetic peptides of a streptococcal surface protein antigen. J Immunol 1991;146:332–336.
  48. Taubman MA, Holmberg CJ, Smith DJ: Immunization of rats with synthetic peptide constructs from the glucan-binding or catalytic region of mutans streptococcal glucosyltransferase protects against dental caries. Infect Immun 1995;63:3088–3093.
  49. Vajdy M, Lycke N: Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology 1993;80:197–203.
  50. Weintraub JA, Hilton JF, White JM, Hoover C, Pelino JE, Tran K, Wycoff K, Larrick JW, Yu L, Featherstone JDB: Results of a plant-derived mutans streptococci antibody clinical trial (abstract 201). J Dent Res 2001;80(special issue).
  51. Wu HY, Abdu S, Stinson D, Russell MW: Generation of female genital tract antibody responses by local or central (common) mucosal immunization. Infect Immun 2000;68:5539–5545.
  52. Zhang P, Jespersgaard C, Lamberty-Mallory L, Katz J, Huang Y, Hajishengallis G, Michalek SM: Enhanced immunogenicity of a genetic chimeric protein consisting of two virulence antigens of Streptococcus mutans and protection against infection. Infect Immun 2002;70:6779–6787.

 goto top of outline Author Contacts

Michael W. Russell, PhD
Department of Microbiology, Farber 138
University at Buffalo, 3435 Main Street
Buffalo, NY 14214 (USA)
Tel. +1 716 829 2790, Fax +1 716 829 2169, E-Mail

 goto top of outline Article Information

Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 2, Number of References : 53

 goto top of outline Publication Details

Caries Research (Journal of the European Organization for Caries Research (ORCA))
Journal founded 1967 by Y. Ericsson; edited 1970–1987 by K.G. König; 1987–1994 by J.M. ten Cate; 1994–2000 by J. Tenovuo

Vol. 38, No. 3, Year 2004 (Cover Date: May-June 2004)

Journal Editor: R.P. Shellis, Bristol
ISSN: 0008–6568 (print), 1421–976X (Online)

For additional information:

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.